Shannon R McCurdy
Overview
Explore the profile of Shannon R McCurdy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greenberg P, Stone R, Abaza Y, Al-Kali A, Anand S, Ball B, et al.
J Natl Compr Canc Netw
. 2025 Mar;
23(3):66-75.
PMID: 40073835
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has...
2.
Munshi P, Olin R, Wall S, McCurdy S, Al-Juhaishi T, Baker J, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39961473
Geriatric assessment (GA) may identify vulnerabilities and promote risk-stratification in older adults predisposed to toxicities after autologous (auto), allogeneic (allo) hematopoietic cell transplantation (HCT) and chimeric antigen T-cell therapies (CAR...
3.
Wang X, Gimotty P, Matthews A, Mamtani R, Luger S, Hexner E, et al.
Blood Adv
. 2025 Jan;
9(3):533-544.
PMID: 39888631
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with...
4.
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Onoue T, Matthews A, Vakilpour A, Kang Y, Lefebvre B, Smith A, et al.
Cardiooncology
. 2024 Nov;
10(1):75.
PMID: 39487530
Venetoclax is a promising drug for patients with acute myeloid leukemia (AML) ineligible for anthracycline-based treatments. In rats, venetoclax is reported to cause myocardial injury. Our objectives were to report...
5.
Bhagwat A, Torres L, Shestova O, Shestov M, Mellors P, Fisher H, et al.
Nat Med
. 2024 Sep;
30(12):3697-3708.
PMID: 39333315
Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in AML has not recapitulated the...
6.
Kongtim P, Vittayawacharin P, Zou J, Srour S, Shaffer B, Shapiro R, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1139-1154.
PMID: 39260570
Donor-specific anti-HLA antibodies (DSA) are an important cause of engraftment failure and may negatively impact survival outcomes of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) using an HLA-mismatched allograft....
7.
Kosmicki J, Marcketta A, Sharma D, Di Gioia S, Batista S, Yang X, et al.
Nat Genet
. 2024 Aug;
56(8):1592-1596.
PMID: 39103650
Coronavirus disease 2019 (COVID-19) and influenza are respiratory illnesses caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses, respectively. Both diseases share symptoms and clinical risk...
8.
Hadjis A, McCurdy S
Front Immunol
. 2024 May;
15:1358668.
PMID: 38817602
Allogeneic hematopoietic cell transplantation (HCT) has transformed over the past several decades through enhanced supportive care, reduced intensity conditioning (RIC), improved human leukocyte antigen (HLA) typing, and novel graft-versus-host disease...
9.
Mangan B, DuMontier C, Hopkins J, Abel G, McCurdy S
Am Soc Clin Oncol Educ Book
. 2024 May;
44(3):e432220.
PMID: 38788182
Hematologic malignancies most often present in the sixth or seventh decade of life. Even so, many older adults may be unable to tolerate standard chemotherapy or require supplementary care or...
10.
Connor M, Prathapa N, Frey N, Gill S, Hexner E, Bruno X, et al.
Haematologica
. 2024 Apr;
109(8):2732-2737.
PMID: 38634143
No abstract available.